Bausch Health Companies Inc. BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduat

VAUGHAN, Ontario, October 12, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance […]

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.

Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announces that SILIQ® (brodalumab injection) is now listed under Alberta's public drug plan for eligible patients who meet the applicable reimbursement criteria.

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.